Sensex
82,408.17 profit arw 1,046.30 (1.29%)
Nifty
25,112.40 profit arw 319.15 (1.29%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 12-Jun-2025
Hot Pursuit
12-Jun-2025     09:55

Zydus Life receives USFDA EIR for Gujarat facility

The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the review, the inspection has been classified as no action indicated (NAI). The USFDA has concluded that the inspection is now closed.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24.

Shares of Zydus Lifesciences shed 0.36% to Rs 975.20 on the BSE.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

82,408.17 1,046.30 (1.29%)

Nifty

25,112.40 319.15 (1.29%)

GLOBAL INDICES

USD

85.75 0.06 (0.95%)

NASDAQ
HANG SENG

23,530.49 292.74(1.26%)